Further MSC trials are also demonstrating benefits in relation to COVID-19, which many have posted previously - here is another ... time to get things moving Novartis / Mesoblast
@BonusBio demonstrated promising efficacy in their Phase I/II clinical trial using their #MSC product that reduced tissue damage (including muscle tissue) and alleviated pneumonia in severe #covidー19 patients s/p treatment. #coronavirus #COVID19
Real patient review on Mesoblast treatment, page-16
Add MSB (ASX) to my watchlist
 (20min delay)
|
|||||
|
Last
$1.47 |
Change
0.073(5.20%) |
Mkt cap ! $1.684B | |||
| Open | High | Low | Value | Volume |
| $1.41 | $1.50 | $1.40 | $4.916M | 3.406M |
Buyers (Bids)
| No. | Vol. | Price($) |
|---|---|---|
| 16 | 33620 | $1.47 |
Sellers (Offers)
| Price($) | Vol. | No. |
|---|---|---|
| $1.47 | 883 | 2 |
View Market Depth
| Last trade - 15.05pm 11/11/2024 (20 minute delay) ? |
| MSB (ASX) Chart |